Thrombosis in cancer patients

Doyun Park, Caroline Cromwel, Mala Varma, Ilan Shapira

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Malignancy represents a hypercoagulable state, and thromboembolism is a commonly encountered entity in cancer patients. While incidence of thromboembolism varies amongst different types of malignancy, up to 20% of all venous thromboembolisms (VTEs) are associated with active cancer. Cancer-associated VTE is the second leading cause of mortality in cancer patients and negatively impacts both short- and long-term survivals. Unfortunately, therapeutic options remain limited and costly. Even though low molecular weight heparin agents have proven to be superior to the vitamin K antagonist warfarin in a large phase 3 trial, paucity of randomized trials in this field leaves significant uncertainty regarding optimal duration of therapy past the initial 3-6 months, treatment of recurrent thrombosis, and use of newer anticoagulants. Further research is needed to determine efficacy of novel oral anticoagulants in cancer-related VTEs and the use of these agents is not actively supported by consensus clinical guidelines at present.

Original languageEnglish
Title of host publicationOncology
Number of pages12
ISBN (Electronic)9781119189596
ISBN (Print)9781119189558
StatePublished - 30 Aug 2019


  • Anticoagulation
  • Bleeding
  • Cancer
  • Malignancy
  • Thrombosis


Dive into the research topics of 'Thrombosis in cancer patients'. Together they form a unique fingerprint.

Cite this